SDC1 and Miyoshi myopathy: A phase I clinical trial involving CD138-specific CAR T-cells demonstrated efficacy with tolerable toxicities in five patients with refractory MM, with 4 patients reaching a stable disease state and one demonstrating a marked reduction of MM cells in the peripheral blood (108).